<DOC>
	<DOCNO>NCT01403064</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ALD518 modify course oral mucositis subject head neck cancer receive concomitant chemotherapy radiotherapy</brief_summary>
	<brief_title>Safety Efficacy ALD518 Reducing Oral Mucositis Head Neck Cancer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Have recently diagnose ( &lt; 6 month prior screen visit date ) , pathologically confirm , nonmetastatic SCC oral cavity , oropharynx , hypopharynx larynx treat CRT firstline treatment ; subject history surgical management ( approximately 46 week RT sufficient time postsurgical healing ) eligible Have plan receive continuous course conventional external beam irradiation deliver intensitymodulated radiotherapy ( IMRT ) single daily fraction 2.0 2.2 Gy , cumulative radiation dose 55 72 Gy . Have plan receive standard cisplatin CT regimen administer triweekly ( 80 100 mg/m2 , Days 0 , 21 , 42 ) weekly ( 30 40 mg/m2 ) standard carboplatin regimen administer weekly ( 100 mg/m2 ) Have Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 CRP &lt; 80 mg/L Have adequate hematopoietic , hepatic , renal function screen visit Tumor lip , sinus , salivary gland , nasopharynx unknown primary tumor Metastatic disease ( M1 ) Stage IV C Any prior history head neck cancer Prior radiation head neck Have major surgical procedure , HNC , significant traumatic injury within 4 week prior initiation RT ; anticipation need major surgical procedure clinical trial Active infectious disease , exclude oral candidiasis Have OM screen visit Have history hypersensitivity monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Oral mucositis ; head neck cancer ; chemotherapy ; radiotherapy</keyword>
</DOC>